US Patent

US11918559 — Reduced dose metaxalone formulations

Formulation · Assigned to Primus Pharmceuticals Inc · Expires 2039-07-29 · 13y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects oral dosage forms of metaxalone with improved bioavailability, including those that use a reduced dose.

USPTO Abstract

Oral dosage forms of metaxalone having improved bioavailability in the fed and fasted states, including dosage forms that employ a reduced dose based on such improved bioavailability.

Drugs covered by this patent

Skelaxin (METAXALONE) · Pfizer

Patent Metadata

Patent number: US11918559
Jurisdiction: US
Classification: Formulation
Expires: 2039-07-29
Drug substance claim: No
Drug product claim: Yes
Assignee: Primus Pharmceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.